It would be very interesting to see whether Lilly’s share price will rise along with the marketing of Mounjaro. After all, the clinical research of this drug cost USD2.8 billion. Recently, The New England Journal of Medicine published the result of the “SURMOUNT-1” study on the efficacy and safety of GLP-1/GIP dual-channel receptor agonist Tirzepatide. […]
Contact us: order*at*isyHealth.com